key: cord-0698127-5c6acfs9
authors: Rubio-Rivas, Manuel; Mora-Luján, José María; Formiga, Francesc; Corrales González, Miguel Ángel; García Andreu, María del Mar; Moreno-Torres, Víctor; García García, Gema María; Alcalá Pedrajas, José N; Boixeda, Ramon; Pérez-Lluna, Leticia; Cortés-Rodríguez, Begoña; Mella-Pérez, Carmen; Navas Alcántara, María de la Sierra; López Reboiro, Manuel Lorenzo; Alfaro-Lara, Verónica; Pérez-Martín, Santiago; Martín-Oterino, José Ángel; Gracia Gutiérrez, Anyuli; Martín-Urda Díez-Canseco, Anabel; Comas Casanova, Pere; Pérez García, Cristina; Varona, José F; Gómez-Huelgas, Ricardo; Antón-Santos, Juan-Miguel; Lumbreras-Bermejo, Carlos
title: Clusters of inflammation in COVID-19: descriptive analysis and prognosis on more than 15,000 patients from the Spanish SEMI-COVID-19 Registry
date: 2022-03-02
journal: Intern Emerg Med
DOI: 10.1007/s11739-021-02924-4
sha: 87ce44757805b429a99b0db213eb9bb2e8835d3c
doc_id: 698127
cord_uid: 5c6acfs9

Uncontrolled inflammation following COVID-19 infection is an important characteristic of the most seriously ill patients. The present study aims to describe the clusters of inflammation in COVID-19 and to analyze their prognostic role. This is a retrospective observational study including 15,691 patients with a high degree of inflammation. They were included in the Spanish SEMI-COVID-19 registry from March 1, 2020 to May 1, 2021. The primary outcome was in-hospital mortality. Hierarchical cluster analysis identified 7 clusters. C1 is characterized by lymphopenia, C2 by elevated ferritin, and C3 by elevated LDH. C4 is characterized by lymphopenia plus elevated CRP and LDH and frequently also ferritin. C5 is defined by elevated CRP, and C6 by elevated ferritin and D-dimer, and frequently also elevated CRP and LDH. Finally, C7 is characterized by an elevated D-dimer. The clusters with the highest in-hospital mortality were C4, C6, and C7 (17.4% vs. 18% vs. 15.6% vs. 36.8% vs. 17.5% vs. 39.3% vs. 26.4%). Inflammation clusters were found as independent factors for in-hospital mortality. In detail and, having cluster C1 as reference, the model revealed a worse prognosis for all other clusters: C2 (OR = 1.30, p = 0.001), C3 (OR = 1.14, p = 0.178), C4 (OR = 2.28, p < 0.001), C5 (OR = 1.07, p = 0.479), C6 (OR = 2.29, p < 0.001), and C7 (OR = 1.28, p = 0.001). We identified 7 groups based on the presence of lymphopenia, elevated CRP, LDH, ferritin, and D-dimer at the time of hospital admission for COVID-19. Clusters C4 (lymphopenia + LDH + CRP), C6 (ferritin + D-dimer), and C7 (D-dimer) had the worst prognosis in terms of in-hospital mortality. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11739-021-02924-4.

As of May 2021, COVID-19 has infected more than 170 million people worldwide and caused the death of more than 3.5 million people [1] . Death is largely due to the inflammatory escalation or host cytokine storm secondary to SARS-CoV-2 infection [2] . This inflammatory response has clearly analytically identifiable components [3] . Clinically, most individual patients showed the changes of lymphocyte counts, D-dimer, interleukin-6 (IL-6), C-reactive protein (CRP), ferritin, LDH, etc. Why some patients become more inflamed than others is not known for certain but it is possible that there is a genetic background that facilitates this. Among those patients who present with this exaggerated inflammatory response, different degrees of inflammation have been described that predict the short-term future of these patients [4] . However, this inflammation is far from being homogeneous in all patients. From these studies, we know that the more parameters of analytical inflammation the worse the A complete list of the SEMI-COVID-19 Network members is provided in the Appendix.

prognosis. The next step is to find out if some parameters have more prognostic value than others. In fact, in clinical practice, we see how some patients start their analytical inflammation in one way and others in another. This suggests different pathways and perhaps also different prognoses.

The present study aims to describe the different clusters or differentiated groups of inflammation in COVID-19 and to analyze their prognostic role.

The present study is a retrospective observational study of consecutive patients included in the Spanish SEMI-COVID-19 Registry, created by the Spanish Society of Internal Medicine (SEMI). This is a multicenter, nationwide registry with over 150 hospitals registered so far. From March 1, 2020 to May 1, 2021, 21,962 hospitalized patients were included in the Registry. The characteristics of this registry have been detailed in previous reports [5] . In brief, all included patients were diagnosed by polymerase chain reaction (PCR) test or rapid antigenic test for SARS-CoV-2 taken from a nasopharyngeal sample, sputum, or bronchoalveolar lavage. The collection of data from each patient in terms of sociodemographic data, comorbidities, laboratory data, treatments, and outcomes was verified by the principal investigator of each center through the review of clinical records. All participating centers in the register received confirmation from the relevant Ethics Committees, including Bellvitge University Hospital (PR 128/20). Informed consent was obtained from the subjects.

The inclusion criteria were all patients in the registry with a community (non-nosocomial) SARS-CoV-2 infection and belonging to the high-risk category of inflammation according to our previous report and based on the lab test on admission [4] . This category of high risk is based on the decrease in the lymphocyte count 101.5 mg/L, lactate dehydrogenase (LDH) > 394U/L, ferritin > 1359.9mcg/L, and D-dimer > 1580 ng/mL.

The treatments received were in accordance with the medical guidelines available at the time of the pandemic [6] [7] [8] [9] [10] [11] . In the absence of clinical evidence of any of the treatments at the initial time of the pandemic, their use was allowed off-label.

The primary outcome of the study was in-hospital mortality. Secondary outcomes were the requirement of high-flow nasal cannula (HFNC), non-invasive mechanical ventilation (NIMV), invasive mechanical ventilation (IMV), or ICU admission.

Multiple imputations of missing data were performed. Categorical variables were expressed as absolute numbers and percentages. Continuous variables are expressed as mean plus standard deviation (SD) in the case of parametric distribution or median [IQR] in the case of nonparametric distribution. Differences between groups were assessed using the Chi-square test for categorical variables and ANOVA or Kruskal-Wallis test as appropriate for continuous variables. p values < 0.05 indicated statistical significance.

The cluster analysis was performed by ascendant hierarchical clustering on the 5 laboratory variables previously selected using Ward's minimum variance method with Euclidean squared distance [12] . Results are graphically depicted by a dendrogram. The number of clusters was estimated by the kmeans method. The cluster analysis model was included in a binary logistic regression, taking in-hospital mortality as the dependent variable. We introduced in the multivariate model those variables with a p value < 0.10 in the univariate model. In-hospital mortality between clusters was depicted by the Kaplan-Meier curves with their logarithmic range test (event: death; censored data: hospital discharge).

Statistical analysis was performed by IBM SPSS Statistics for Windows, Version 26.0. Armonk, NY, USA: IBM Corp.

From March 1, 2020 to May 1, 2021, 20,641 patients admitted for non-nosocomial COVID-19 were included in the SEMI-COVID-19 registry. Of these, 15,691 fell into the high-risk category for inflammation according to the laboratory tests at admission and were therefore included in the present study ( Figure S1 ).

Hierarchical cluster analysis identified 7 clearly differentiated clusters (C1-C7) (Fig. 1) . The baseline characteristics of the 7 clusters are shown in Table 1 . It is noteworthy that C1 patients attend the hospital earlier from the onset. C2 and C3 patients have a lower Charlson index. C4 patients are older and predominantly male and have more comorbidity (mainly hypertension and dyslipidemia). C5 patients have more comorbidity (mainly hypertension, dyslipidemia and diabetes mellitus). Patients in groups C6 and C7 are older and have more dependency and comorbidity (mainly hypertension, dyslipidemia and diabetes mellitus).

Symptoms at the time of hospital admission are listed in Table S1 . In particular, group C1 presents more frequently with a headache. C2 and C3 present more frequently with headaches, arthromyalgia, sore throat, cough, diarrhea, anosmia, and ageusia. C4 patients present more frequently with cough, tachypnea, and less diarrhea. Cluster C5 most frequently presents with headache, arthromyalgia, cough, anosmia, and ageusia. Clusters C6 and C7 present less frequently with fever and cough. Table S2 shows the inflammatory analytical parameters presented by each of the clusters. According to the most relevant analytical feature in each group, we can define cluster C1 by the presence of lymphopenia, cluster C2 by elevated ferritin, and C3 by elevated LDH. Cluster C4 is characterized by lymphopenia plus elevated CRP and LDH and often also elevated ferritin. Cluster C5 is defined by elevated CRP, and cluster C6 by elevated ferritin and D-dimer and often also elevated CRP and LDH. Finally, group C7 is characterized by elevated D-dimer. Figure 2 shows the distribution of each of the inflammatory parameters in each cluster.

It should be noted that cluster C4 is the cluster with the lowest PaO2/FiO2 on admission. This fact possibly shows a greater inflammatory component and greater evolution to ARDS. Table S3 shows the treatments received during admission. Logically, the clusters with a greater analytical inflammatory component (C4) received corticosteroids and tocilizumab more frequently. On the other hand, clusters with higher C6 C4 C7 C2 C3 C1 C5 Fig. 1 Dendrogram. Clusters based on analytical inflammatory parameters upon admission. Cluster C1 is characterized by the presence of lymphopenia, cluster C2 by elevated ferritin, and C3 by elevated LDH. Cluster C4 is characterized by lymphopenia plus ele-vated CRP and LDH and frequently also elevated ferritin. Cluster C5 is defined by elevated CRP, and cluster C6 by elevated ferritin and D-dimer and frequently also elevated CRP and LDH. Finally, cluster C7 is characterized by elevated D-dimer D-dimer elevation (C6 and C7) more frequently received high doses of LMWH.

The clusters with the highest in-hospital mortality were C4, C6, and C7 (36.8% vs. 39.3% vs. 26.4%) ( Table 2 ; Fig. 3 ). It is also noteworthy that the C4 cluster with a higher analytical inflammatory component is the group with the highest requirements for HFNC, NIMV, IMV, and ICU admission. On the other hand, the C6 and C7 clusters with greater prominence of D-dimer have high mortality but not so high requirements for HFNC, NIMV, IMV, and ICU admission. Table S4 shows the risk factors for in-hospital mortality. These included age (OR = 1.07, p < 0.001), female sex (OR = 0.71, p < 0.001), Black race (OR = 0.19, p = 0.032), higher BMI (OR = 1.02, p < 0.001), time from disease onset to admission (OR = 0.96, p < 0.001), higher degree The drugs received during admission (steroids, remdesivir, and tocilizumab) were included in the uni-and multivariate models due to their clinical importance and statistical influence on the rest of the variables but, despite reaching statistical significance in the multivariate model, their results must be interpreted with caution since this is not the type of study to assess their efficacy. Asthma was found to be a protective factor for in-hospital death.

In the present study, we demonstrate the presence of 7 clearly differentiated inflammation clusters. It is clear that COVID-19 elicits an exaggerated inflammatory response but it is also clear that patients do not all become inflamed in the same way. Recently, our group had highlighted risk categories based on the degree of analytical inflammation in patients with COVID-19 at the time of hospital admission [4] . We know from that research the additive importance of such analytical inflammatory criteria. We now also know from the present study that it is important not only how many criteria the patient meets but also which ones. And this differentiation in the type of inflammation can be predicted at the time of admission. Afterward, the cascade of inflammation will continue, but the onset of inflammation already translates into differential characteristics and a very important predictive power when it comes to directing our strategies as clinicians.

The fact that the clusters with the worst prognosis C4, C6, and C7 are also those that occur in the older population suggests that age alone is not only a risk factor, but also that this is a population that is more inflamed. Whether this is due to a failure in the autoregulation of inflammatory mechanisms inherent to age should be answered with further studies. They are also clusters with higher associated comorbidity (especially C4) and one would think that those associated diseases provide an inflammatory basis that could influence. However, the C5 cluster also has considerably associated comorbidity and yet does not have as much inflammation at entry. Inflammation clusters add to the list of factors associated with increased in-hospital mortality in COVID-19 [13] [14] [15] . All the clusters have a worse prognosis compared to cluster C1, which we could consider the reference cluster. However, we should focus our efforts on detecting the C4, C6, and C7 clusters first, as they are really the ones with the worst prognosis. The C4 cluster presents a greater inflammatory component in the form of lymphopenia, elevated CRP and LDH, and very frequently, also elevated ferritin. It is a cluster that will evolve to acute respiratory distress syndrome (ARDS) and will require more HFNC, NIMV, IMV, and ICU admission. On the contrary, cluster C7 is a cluster with a prominence of D-dimer. It also has high mortality but clearly requires less HFNC, NIMV, IMV, and ICU admission. This could translate into higher mortality from thromboembolic disease and less progression to ARDS. Finally, cluster C6 is a mixture of clusters C4 and C7, i.e., a cluster with a prominence of D-dimer but also of ferritin and, very frequently, CRP, LDH, and lymphopenia.

Whether these 7 clusters respond to different pathways of inflammation and perhaps respond to genetic differences that condition a different host response to the same external aggression of SARS-CoV-2 is something that we cannot answer with the present study. As we have discussed previously, the inflammation cascade in patients with COVID-19 does not occur equally in all patients. In Fig. 4 , we propose a logical sequence in the inflammation of these patients. It is based on the analytical characteristics of each of them and the additive possibilities. It also has a pathophysiological penias. After this first step, vascular endothelial damage occurs and there appears the elevation of D-dimer. Cluster C7 suggests that there is a group of patients who present endothelial damage with subsequent micro-or macrothrombosis without going through a previous step of major inflammation logic behind it as the initiation of the inflammatory cascade in COVID-19 is defined by macrophage activation. This includes elevation of LDH, IL6, CRP, ferritin, and cytopenias. Why some patients elevate some parameters earlier and other patients elevate others is unknown. After this first step, vascular endothelial damage occurs and there appears the elevation of D-dimer. From such a model, there are several comments to consider. First, there are 3 clusters that should sound the alarm when detected, such as clusters C4, C6, and C7. They translate more advanced stages of the disease and early action should be taken to block such escalation. On the other hand, cluster C2 does not represent such an advanced stage of inflammation but possibly the transition to cluster C6 is just around the corner in these patients (compared to clusters C1, C3, and C5 where we would have more room for maneuver). Thus, ferritin and D-dimer should be the key indicators of increased risk in patients hospitalized for COVID-19. Finally, cluster C7 suggests that there is a group of patients who present endothelial damage with subsequent micro-or macrothrombosis without going through a previous step of major inflammation. This is a puzzling fact that should make us rethink the doses of LMWH in patients with little inflammation.

Of all the treatments tested in COVID-19, it is the immunosuppressants/immunomodulators (corticosteroids and tocilizumab) that have demonstrated the greatest effectiveness to date [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . They are especially indicated in those patients with analytical parameters of inflammation such as the patients included in the present study. However, it is plausible to think that their effectiveness is not the same in all inflammation clusters. We believe that perhaps in C4 (with a greater inflammatory component) and even C6 they could clearly demonstrate their benefit but perhaps in C7, with a greater role of D-dimer, they might not be so useful.

In conclusion, the present study identifies 7 inflammation groups based on the presence of lymphopenia, elevated CRP, LDH, ferritin, and D-dimer at the time of hospital admission for COVID-19. Clusters C4 (lymphopenia + LDH + CRP), C6 (ferritin + D-dimer), and C7 (D-dimer) were the worst prognostic clusters in terms of in-hospital mortality.

Coordinator of the SEMI-COVID-19 Registry: José Manuel Casas Rojo. 

The cytokine storm and COVID-19

The most important biomarker associated with coagulation and inflammation among COVID-19 patients

Risk categories in COVID-19 based on degrees of inflammation. Data on more than 17,000 patients from the Spanish SEMI-COVID-19 registry

Núñez-Cortés 2020 Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 Registry

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial

A Trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19

Compassionate use of remdesivir for patients with severe Covid-19

Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study

A Recovery Collaborative Group P Horby WS Lim 2020 Dexamethasone in hospitalized patients with Covid-19

Principal component methods -hierarchical clustering -partitional clustering: why would we need to choose for visualizing data?

Clinical course and risk factors for mortality of adult inpatients 434 with COVID-19 in Wuhan, China: a retrospective cohort study

Impact of arterial stiffness on all-cause mortality in patients hospitalized with COVID-19 in Spain Hypertension

Predicting clinical outcome with phenotypic clusters in COVID-19 pneumonia: an analysis of 12,066 hospitalized patients from the Spanish registry SEMI-COVID-19

Dexamethasone in hospitalized patients with Covid-19

Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness

Beidh REMAP-CAP Investigators 2021 Interleukin-6 receptor antagonists in critically Ill patients with Covid-19

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label

Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis-first update

The use of corticosteroids or tocilizumab in COVID-19 based on inflammatory markers

Real-life impact of glucocorticoid treatment in COVID-19 mortality: a multicenter retrospective study

Evolution of the use of corticosteroids for the treatment of hospitalised COVID-19 patients in spain between march and november 2020: SEMI-COVID National Registry

High-dose methylprednisolone pulses for 3 days vs. low-dose dexamethasone for 10 days in severe, non-critical COVID-19: a retrospective propensity score matched analysis

Beneficial and harmful outcomes of tocilizumab in severe COVID-19: a systematic review and meta-analysis Pharmacotherapy 41 11

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Acknowledgements We gratefully acknowledge all the investigators who participate in the SEMI-COVID-19 Registry. We also thank the SEMI-COVID-19 Registry Coordinating Center for their quality control data, logistic and administrative support.Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

The authors declare they have no conflict of interest.

The study has been approved by the ethics committee of Bellvitge University Hospital.Informed consent Informed consent was obtained from the subjects.Authorship All authors had access to the data and a role in writing this manuscript.

The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s11739-021-02924-4.

Manuel Rubio-Rivas 1 · José María Mora-Luján 1 · Francesc Formiga 1 · Miguel Ángel Corrales González 2 · María del Mar García Andreu 3 · Víctor Moreno-Torres 4 · Gema María García García 5 · José N Alcalá Pedrajas 6 · Ramon Boixeda 7 · Leticia Pérez-Lluna 8 · Begoña Cortés-Rodríguez 9 · Carmen Mella-Pérez 10 · María de la Sierra Navas Alcántara 11 · Manuel Lorenzo López Reboiro 12 · Verónica Alfaro-Lara 13 · Santiago Pérez-Martín 14 · José Ángel Martín-Oterino 15 · Anyuli Gracia Gutiérrez 16